TP53 and plasma cell myeloma: Regarding its clinical relevance, while this isoform represents a marker of good prognosis in colon cancer [24], AML (acute myeloid leukemia) [53], and renal cell carcinoma [54], the expression of p53β was instead associated with worse survival in ovarian cancers with a wild-type TP53 status [55], with reduced cutaneous melanoma-specific survival [56], and with tumor progression in multiple myeloma patients [57].